Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 24, 2020

Ipilimumab and Nivolumab Immunotherapy in Advanced NETs

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Immunotherapy of Ipilimumab and Nivolumab in Patients With Advanced Neuroendocrine Tumours: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
Clin. Cancer Res 2020 Jun 12;[EPub Ahead of Print], O Klein, D Kee, B Markman, M Michael, CR Underhill, MS Carlino, L Jackett, C Lum, CL Scott, A Nagrial, A Behren, JY So, J Palmer, JS Cebon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading